Compare Sun Pharma with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs STRIDES PHARMA SCIENCE - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA STRIDES PHARMA SCIENCE SUN PHARMA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 77.1 45.1 170.9% View Chart
P/BV x 3.3 2.1 156.2% View Chart
Dividend Yield % 0.6 0.2 280.2%  

Financials

 SUN PHARMA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    SUN PHARMA
Mar-20
STRIDES PHARMA SCIENCE
Mar-18
SUN PHARMA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs4841,147 42.2%   
Low Rs315642 49.1%   
Sales per share (Unadj.) Rs136.9317.2 43.1%  
Earnings per share (Unadj.) Rs17.57.8 222.4%  
Cash flow per share (Unadj.) Rs26.025.1 103.8%  
Dividends per share (Unadj.) Rs4.002.00 200.0%  
Dividend yield (eoy) %1.00.2 447.6%  
Book value per share (Unadj.) Rs188.7274.3 68.8%  
Shares outstanding (eoy) m2,399.2689.50 2,680.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.92.8 103.6%   
Avg P/E ratio x22.9114.0 20.1%  
P/CF ratio (eoy) x15.435.7 43.0%  
Price / Book Value ratio x2.13.3 64.9%  
Dividend payout %22.925.5 89.9%   
Avg Mkt Cap Rs m958,86480,058 1,197.7%   
No. of employees `00017.82.5 708.4%   
Total wages/salary Rs m63,6244,341 1,465.8%   
Avg. sales/employee Rs Th18,490.611,325.8 163.3%   
Avg. wages/employee Rs Th3,582.61,731.4 206.9%   
Avg. net profit/employee Rs Th2,357.6280.1 841.8%   
INCOME DATA
Net Sales Rs m328,37528,394 1,156.5%  
Other income Rs m6,360941 676.1%   
Total revenues Rs m334,73529,334 1,141.1%   
Gross profit Rs m69,8983,965 1,762.7%  
Depreciation Rs m20,5281,540 1,332.6%   
Interest Rs m3,0271,962 154.3%   
Profit before tax Rs m52,7021,403 3,755.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m-2,606-436 598.1%   
Tax Rs m8,22897 8,456.3%   
Profit after tax Rs m41,868702 5,963.2%  
Gross profit margin %21.314.0 152.4%  
Effective tax rate %15.66.9 225.1%   
Net profit margin %12.82.5 515.6%  
BALANCE SHEET DATA
Current assets Rs m316,54224,836 1,274.5%   
Current liabilities Rs m157,06418,993 827.0%   
Net working cap to sales %48.620.6 236.0%  
Current ratio x2.01.3 154.1%  
Inventory Days Days8871 123.4%  
Debtors Days Days105113 92.3%  
Net fixed assets Rs m243,10234,289 709.0%   
Share capital Rs m2,399895 268.1%   
"Free" reserves Rs m450,24523,651 1,903.7%   
Net worth Rs m452,64524,546 1,844.1%   
Long term debt Rs m20,28915,513 130.8%   
Total assets Rs m682,52565,437 1,043.0%  
Interest coverage x18.41.7 1,073.4%   
Debt to equity ratio x00.6 7.1%  
Sales to assets ratio x0.50.4 110.9%   
Return on assets %6.64.1 161.5%  
Return on equity %9.22.9 323.4%  
Return on capital %11.26.9 162.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m74,21915,697 472.8%   
Fx outflow Rs m27,964735 3,802.5%   
Net fx Rs m46,25514,962 309.2%   
CASH FLOW
From Operations Rs m65,5481,871 3,503.9%  
From Investments Rs m-25,8885,826 -444.4%  
From Financial Activity Rs m-57,151-10,157 562.7%  
Net Cashflow Rs m-13,857-2,615 529.9%  

Share Holding

Indian Promoters % 63.7 27.7 230.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 37.8 13.6%  
FIIs % 23.0 8.6 267.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 25.9 32.0%  
Shareholders   133,026 56,241 236.5%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   TTK HEALTHCARE  ALEMBIC  WYETH  CADILA HEALTHCARE  SUVEN LIFE SCIENCES  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 598 Points Lower, Nifty Settles Below 15,100-Mark; HDFC and JSW Steel Top Losers(Closing)

Indian share markets witnessed huge selling during closing hours today and ended their day deep in the red.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Mar 4, 2021 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - J.B.CHEMICALS COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS